Pharmacopsychiatry最新文献

{"title":"Medical Cannabis Legalization: No Contribution to Rising Stimulant Rates in the USA.","authors":"Garrett D Alexander, Luke R Cavanah, Jessica L Goldhirsh, Leighton Y Huey, Brian J Piper","doi":"10.1055/a-2152-7757","DOIUrl":"10.1055/a-2152-7757","url":null,"abstract":"<p><strong>Introduction: </strong>There has been a pronounced increase in the use of Schedule II stimulants to treat attention-deficit hyperactivity disorder (ADHD) in the United States over the last two decades. Interestingly, chronic medical cannabis (MC) use can present with cognitive impairments that resemble ADHD symptoms. This study aimed to determine if MC legalization increased prescription stimulant distribution.</p><p><strong>Methods: </strong>Information on the distribution of methylphenidate, amphetamine, and lisdexamfetamine for 2006 to 2021 was extracted from the Drug Enforcement Administration's comprehensive database and the three-year population-corrected slopes of stimulant distribution before and after MC program implementation were compared.</p><p><strong>Results: </strong>We found a significant main effect of time (<i>p</i><0.001); however, contrary to the hypothesis, the sales status of states' MC, did not influence slopes of distribution (<i>p</i>=0.391). There was a significantly large interaction effect of time and MC sales status on slopes of distribution (<i>p</i><0.001). Slopes of distribution rates of stimulants were significantly lower in states that proceeded to legalize MC prior to MC program implementation than those states that did not (<i>p</i>=0.022). After MC program implementation, however, the distribution rates of the Schedule II stimulants were not significantly different when comparing states with MC sales to those without (<i>p</i>=0.355).</p><p><strong>Discussion: </strong>These findings suggest that MC program legalization did not contribute to certain states having rapid increases in Schedule II stimulant distribution rates over time. Other factors, including the liberalization of the adult ADHD diagnostic criteria in the DSM-5 and the introduction of Binge Eating Disorder, also likely contributed to elevations in stimulant distribution.</p>","PeriodicalId":19783,"journal":{"name":"Pharmacopsychiatry","volume":null,"pages":null},"PeriodicalIF":4.3,"publicationDate":"2023-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"54230500","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clozapine-Induced Stuttering: Case Report and Literature Review.","authors":"Fares Jaballah, Amina Aissa, Uta Ouali, Yosra Zgueb, Rabaa Jomli","doi":"10.1055/a-2189-5597","DOIUrl":"10.1055/a-2189-5597","url":null,"abstract":"","PeriodicalId":19783,"journal":{"name":"Pharmacopsychiatry","volume":null,"pages":null},"PeriodicalIF":4.3,"publicationDate":"2023-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"72015030","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Lithium Therapy in Old Age: Recommendations from a Delphi Survey.","authors":"Julia Christl,&nbsp;Bruno Müller-Oerlinghausen,&nbsp;Michael Bauer,&nbsp;Daniel Kamp,&nbsp;Fabian Fußer,&nbsp;Jens Benninghoff,&nbsp;Rosa A Fehrenbach,&nbsp;Christian Lange-Asschenfeldt,&nbsp;Michael Rapp,&nbsp;Bernd Ibach,&nbsp;Rainer Schaub,&nbsp;Axel Wollmer,&nbsp;Timm Strotmann-Tack,&nbsp;Michael Hüll,&nbsp;Susanne Biermann,&nbsp;Katharina Roscher,&nbsp;Bernd Meissnest,&nbsp;Alexander Menges,&nbsp;Bernd Weigel,&nbsp;Dorothee Maliszewski-Makowka,&nbsp;Christian Mauerer,&nbsp;Martin Schaefer,&nbsp;Beate Joachimsmeier,&nbsp;Sarah Kayser,&nbsp;Lars Christian Rump,&nbsp;Tillmann Supprian","doi":"10.1055/a-2117-5200","DOIUrl":"https://doi.org/10.1055/a-2117-5200","url":null,"abstract":"<p><strong>Introduction: </strong>While lithium (Li) has been well established for the treatment of bipolar disorder, geriatric patients require special attention when it comes to issues of drug safety. Declining renal function, amongst other medical conditions, and polypharmacy may pose increased risks. Only a few previous studies have addressed the management of Li in geriatric patients.</p><p><strong>Methods: </strong>Twenty-four German medical experts on geriatric medicine and Li treatment participated in a Delphi survey, consisting of two rounds of questionnaires and a final formulation of treatment recommendations. Three major issues of Li therapy were outlined: initiation of treatment, monitoring of ongoing therapy, and withdrawal due to medical reasons. Final recommendations were consented to at a threshold of at least 80% expert agreement.</p><p><strong>Results: </strong>Final consensus was achieved on 21 clinical recommendations. The approved recommendations covered aspects of necessary laboratory checks, concomitant medication, and target Li serum concentration in geriatric patients. Concerning the termination of Li therapy, an agreement was reached on the appropriate time span for tapering and on potential alternatives to Li. No consensus was achieved on whether concomitant dementia or frailty should be considered contraindications for Li treatment and the appropriate threshold of the estimated glomerular function rate for withdrawing Li.</p><p><strong>Conclusion: </strong>According to the view of German experts, Li may be used in geriatric patients, but it should be monitored carefully. However, the lack of consent in several specific treatment situations underlines the need for research on specific issues of Li therapy.</p>","PeriodicalId":19783,"journal":{"name":"Pharmacopsychiatry","volume":null,"pages":null},"PeriodicalIF":4.3,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/ab/57/10-1055-a-2117-5200.PMC10484639.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10194379","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correction: Lithium Therapy in Old Age: Recommendations from a Delphi Survey.","authors":"Julia Christl, Bruno Müller-Oerlinghausen, Michael Bauer, Daniel Kamp, Fabian Fußer, Jens Benninghoff, Rosa A Fehrenbach, Christian Lange-Asschenfeldt, Michael Rapp, Bernd Ibach, Rainer Schaub, Axel Wollmer, Timm Strotmann-Tack, Michael Hüll, Susanne Biermann, Katharina Roscher, Bernd Meissnest, Alexander Menges, Bernd Weigel, Dorothee Maliszewski-Makowka, Christian Mauerer, Martin Schaefer, Beate Joachimsmeier, Sarah Kayser, Lars Christian Rump, Tillmann Supprian","doi":"10.1055/a-2158-9744","DOIUrl":"10.1055/a-2158-9744","url":null,"abstract":"","PeriodicalId":19783,"journal":{"name":"Pharmacopsychiatry","volume":null,"pages":null},"PeriodicalIF":3.6,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11333121/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10235118","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effects of Early Clozapine Treatment on Remission Rates in Acute Schizophrenia (The EARLY Trial): Protocol of a Randomized-Controlled Multicentric Trial.","authors":"Elias Wagner, Wolfgang Strube, Thomas Görlitz, Aslihan Aksar, Ingrid Bauer, Mattia Campana, Joanna Moussiopoulou, Alexander Hapfelmeier, Petra Wagner, Silvia Egert-Schwender, Robert Bittner, Kathrin Eckstein, Igor Nenadić, Tilo Kircher, Berthold Langguth, Eva Meisenzahl, Martin Lambert, Sigrid Neff, Berend Malchow, Peter Falkai, Dusan Hirjak, Kent-Tjorben Böttcher, Andreas Meyer-Lindenberg, Christiane Blankenstein, Stefan Leucht, Alkomiet Hasan","doi":"10.1055/a-2110-4259","DOIUrl":"10.1055/a-2110-4259","url":null,"abstract":"<p><strong>Background: </strong>Quick symptomatic remission after the onset of psychotic symptoms is critical in schizophrenia treatment, determining the subsequent disease course and recovery. In this context, only every second patient with acute schizophrenia achieves symptomatic remission within three months of initiating antipsychotic treatment. The potential indication extension of clozapine-the most effective antipsychotic-to be introduced at an earlier stage (before treatment-resistance) is supported by several lines of evidence, but respective clinical trials are lacking.</p><p><strong>Methods: </strong>Two hundred-twenty patients with acute non-treatment-resistant schizophrenia will be randomized in this double-blind, 8-week parallel-group multicentric trial to either clozapine or olanzapine. The primary endpoint is the number of patients in symptomatic remission at the end of week 8 according to international consensus criteria ('Andreasen criteria'). Secondary endpoints and other assessments comprise a comprehensive safety assessment (i. e., myocarditis screening), changes in psychopathology, global functioning, cognition, affective symptoms and quality of life, and patients' and relatives' views on treatment.</p><p><strong>Discussion: </strong>This multicentre trial aims to examine whether clozapine is more effective than a highly effective second-generation antipsychotics (SGAs), olanzapine, in acute schizophrenia patients who do not meet the criteria for treatment-naïve or treatment-resistant schizophrenia. Increasing the likelihood to achieve symptomatic remission in acute schizophrenia can improve the overall outcome, reduce disease-associated burden and potentially prevent mid- and long-term disease chronicity.</p>","PeriodicalId":19783,"journal":{"name":"Pharmacopsychiatry","volume":null,"pages":null},"PeriodicalIF":4.3,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/ff/93/10-1055-a-2110-4259.PMC10484642.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10194380","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Longitudinal Digital Mood Charting in Bipolar Disorder: Experiences with ChronoRecord Over 20 Years.","authors":"Michael Bauer,&nbsp;Tasha Glenn,&nbsp;Martin Alda,&nbsp;Paul Grof,&nbsp;Rita Bauer,&nbsp;Ulrich W Ebner-Priemer,&nbsp;Stefan Ehrlich,&nbsp;Andrea Pfennig,&nbsp;Maximilian Pilhatsch,&nbsp;Natalie Rasgon,&nbsp;Peter C Whybrow","doi":"10.1055/a-2156-5667","DOIUrl":"https://doi.org/10.1055/a-2156-5667","url":null,"abstract":"<p><strong>Introduction: </strong>Longitudinal study is an essential methodology for understanding disease trajectories, treatment effects, symptom changes, and long-term outcomes of affective disorders. Daily self-charting of mood and other illness-related variables is a commonly recommended intervention. With the widespread acceptance of home computers in the early 2000s, automated tools were developed for patient mood charting, such as ChronoRecord, a software validated by patients with bipolar disorder. The purpose of this study was to summarize the daily mood, sleep, and medication data collected with ChronoRecord, and highlight some of the key research findings. Lessons learned from implementing a computerized tool for patient self-reporting are also discussed.</p><p><strong>Methods: </strong>After a brief training session, ChronoRecord software for daily mood charting was installed on a home computer and used by 609 patients with affective disorders.</p><p><strong>Results: </strong>The mean age of the patients was 40.3±11.8 years, a mean age of onset was 22±11.2 years, and 71.4% were female. Patients were euthymic for 70.8% of days, 15.1% had mild depression, 6.6% had severe depression, 6.6% had hypomania, and 0.8% had mania. Among all mood groups, 22.4% took 1-2 medications, 37.2% took 3-4 medications, 25.7 took 5-6 medications, 11.6% took 7-8 medications, and 3.1% took >8 medications.</p><p><strong>Conclusion: </strong>The daily mood charting tool is a useful tool for increasing patient involvement in their care, providing detailed patient data to the physician, and increasing understanding of the course of illness. Longitudinal data from patient mood charting was helpful in both clinical and research settings.</p>","PeriodicalId":19783,"journal":{"name":"Pharmacopsychiatry","volume":null,"pages":null},"PeriodicalIF":4.3,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/71/7a/10-1055-a-2156-5667.PMC10484643.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10196961","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Valproic Acid Induced Thrombocytopenia in an Elderly Man with Schizoaffective Disorder: A Case Report.","authors":"Yun Tien","doi":"10.1055/a-2142-8708","DOIUrl":"https://doi.org/10.1055/a-2142-8708","url":null,"abstract":"This article reports an elderly male patient who has been diagnosed with chronic and refractory schizoaffective disorder. In an effort to manage his manic symptoms, he received a combination of clozapine, aripiprazole, and valproic acid as treatment. During the weekly complete blood count (CBC) test being done as part of his clozapine therapy, we incidentally discovered that he had developed asymptomatic thrombocytopenia, which we attributed to the valproic acid.","PeriodicalId":19783,"journal":{"name":"Pharmacopsychiatry","volume":null,"pages":null},"PeriodicalIF":4.3,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10206978","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Does Lidocaine Shorten Seizure Duration in Electroconvulsive Therapy?","authors":"Jose López-Ilundain,&nbsp;Alejandro Ballesteros Prados,&nbsp;Ángela S Rosero Enriquez,&nbsp;Mónica Enguita-Germán,&nbsp;Estefania Uriarte Rosquil,&nbsp;Jose López Gil,&nbsp;Ana Marmol Fábrega,&nbsp;Estitxu Martinez de Zabarte Moraza,&nbsp;Alex R Maughan,&nbsp;Javier Yoldi-Murillo","doi":"10.1055/a-2114-4327","DOIUrl":"https://doi.org/10.1055/a-2114-4327","url":null,"abstract":"<p><strong>Background: </strong>Electroconvulsive therapy (ECT) is an effective short-term treatment for schizophrenia and depression, amongst other disorders. Lidocaine is typically added to reduce pain from intravenous propofol injection. However, depending on the dose used in the ECT setting, it can shorten seizure duration. The aim of this study was to investigate the effect of lidocaine dose on seizure duration.</p><p><strong>Methods: </strong>This retrospective, naturalistic cohort study included 169 patients treated with ECT. We examined 4714 ECT sessions with propofol or propofol plus lidocaine. Ictal quality was manually rated by visual inspection. The main outcome of this study was the relation of lidocaine with seizure duration after controlling for socio-demographic, ECT, and other anesthetic variables.</p><p><strong>Results: </strong>There was a significant negative association between lidocaine usage and seizure duration. Multivariate analyses showed that seizure duration was shortened by an average of 3.21 s in sessions with lidocaine. Moreover, in this subgroup, there was a significant negative dose-dependent association between lidocaine dose and seizure length. Complementarily, a significant positive association between preictal BIS and seizure length was found in the subgroup of sessions where preictal was used.</p><p><strong>Conclusions: </strong>We provide additional evidence highlighting the importance of caution regarding lidocaine dosing due to the effect on seizure length in the ECT setting. It is advisable for clinicians to exercise caution when administering lidocaine regarding its dosing and seizure length in ECT settings. Future investigation is needed to assess causal relationships by studying certain vulnerable groups or employing other charge calculation techniques, such as the titration method.</p>","PeriodicalId":19783,"journal":{"name":"Pharmacopsychiatry","volume":null,"pages":null},"PeriodicalIF":4.3,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10197262","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Establishing Core Symptoms of Acute Serotonin Reuptake Inhibitor Withdrawal: Results from an International Survey of Online Peer-Support Communities.","authors":"Bryan Shapiro,&nbsp;Eric Kramer,&nbsp;Dina Khoury,&nbsp;Adrian Preda","doi":"10.1055/a-2078-4593","DOIUrl":"https://doi.org/10.1055/a-2078-4593","url":null,"abstract":"<p><strong>Background: </strong>Serotonin reuptake inhibitor (SRI) antidepressants are commonly associated with withdrawal reactions. The Discontinuation Emergent Signs and Symptoms (DESS) checklist has been considered the gold standard research and screening tool for SRI withdrawal but has several limitations, including its length, lack of specificity, and omission of baseline symptom and symptom severity scores, making it impractical for use in clinical or research settings. We investigated the prevalence and severity of common SRI withdrawal symptoms to determine whether a very small subset of symptoms can capture most occurrences of SRI withdrawal.</p><p><strong>Methods: </strong>We surveyed 344 members of online peer-support communities aged 18-65, reporting withdrawal symptoms after chronic SRI treatment. The severity of nine common withdrawal symptoms was evaluated at baseline and during the withdrawal period.</p><p><strong>Results: </strong>Dizziness, brain zaps, irritability/agitation, and anxiety/nervousness demonstrated the largest increase in severity during withdrawal relative to baseline. Nearly all (97.7%) of the 344 subjects and all (100%) 153 subjects with relatively low baseline symptom scores (total<5) reported a worsening of one of these four symptoms. The presence of a baseline anxiety disorder did not affect rates of withdrawal-emergent anxiety/nervousness.</p><p><strong>Conclusion: </strong>Nearly all surveyed subjects reported worsening either of dizziness, brain zaps, irritability/agitation, or anxiety/nervousness in acute withdrawal. A screening test incorporating these four core symptoms may be sufficiently sensitive to rule out SRI withdrawal and may be valuable in clinical and research settings. Incorporating withdrawal symptom severity may further enhance specificity.</p>","PeriodicalId":19783,"journal":{"name":"Pharmacopsychiatry","volume":null,"pages":null},"PeriodicalIF":4.3,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9794781","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"GABAergic Effects of Etifoxine and Alprazolam Assessed by Double Pulse TMS.","authors":"Marco Riebel,&nbsp;Benedikt von Pappenheim,&nbsp;Carolina Kanig,&nbsp;Caroline Nothdurfter,&nbsp;Thomas C Wetter,&nbsp;Rainer Rupprecht,&nbsp;Jens Schwarzbach","doi":"10.1055/a-2078-4823","DOIUrl":"https://doi.org/10.1055/a-2078-4823","url":null,"abstract":"<p><strong>Introduction: </strong>There is a need for novel anxiolytics with improved side effect profiles compared to benzodiazepines. A promising candidate with alternative pharmacodynamics is the translocator protein ligand, etifoxine.</p><p><strong>Methods: </strong>To get further insight into its mechanisms of action and side effects compared to the benzodiazepine alprazolam, we performed a double-blind, placebo-controlled, repeated-measures study in 36 healthy male subjects. Participants were examined for trait anxiety and side effects and underwent repeated transcranial magnetic stimulation (TMS) assessments, including motor evoked potentials (MEP), short intracortical inhibition (SICI), intracortical facilitation (ICF), and cortical silent period (CSP).</p><p><strong>Results: </strong>We observed attenuation of MEPs by alprazolam but not by etifoxine. SICI was not significantly affected by alprazolam or etifoxine. However, the response pattern indicated a lowered SICI threshold after the administration of etifoxine and alprazolam compared to the placebo. ICF and CSP were influenced by neither medication. Alprazolam led to higher sedation and subjective impairment of concentration compared to etifoxine. Individual anxiety trait scores did not affect TMS parameters.</p><p><strong>Discussion: </strong>This study indicated a favorable side effect profile of etifoxine in healthy volunteers. Moreover, it revealed differential GABA-related effects on neuromuscular function by means of TMS. The side effects and TMS profile of etifoxine are compatible with the involvement of neurosteroidogenesis and a predominant α3 subunit modulation compared to alprazolam.</p>","PeriodicalId":19783,"journal":{"name":"Pharmacopsychiatry","volume":null,"pages":null},"PeriodicalIF":4.3,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10152800","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}